CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹27,548 Cr | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr |
What is the latest Revenue of CIPLA ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹27,548 Cr |
| Mar2025 | ₹25,774 Cr |
| Mar2024 | ₹22,753 Cr |
| Mar2023 | ₹21,763 Cr |
| Mar2022 | ₹19,160 Cr |
How is Revenue of CIPLA Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹27,548 Cr | 6.88 | |
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | - | |
Compare Revenue of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹115,256.9 Cr | -1.8% | 3.2% | -4.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹461,644.0 Cr | 1.1% | 7.2% | 15.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹184,053.0 Cr | 2.4% | 4.2% | -1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹167,464.0 Cr | 1.9% | 8.3% | 45.6% | Stock Analytics | |
| MANKIND PHARMA | ₹103,631.0 Cr | -0.9% | 5.8% | 3.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,049.0 Cr | -8.8% | -3.2% | -4.6% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -1.8% |
3.2% |
-4.9% |
| SENSEX | -0.9% |
4.9% |
-6.8% |
You may also like the below Video Courses